TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors

Uri Tabori, Adam Shlien, Berivan Baskin, Sarah Levitt, Peter Ray, Noa Alon, Cynthia Hawkins, Eric Bouffet, Malgorzata Pienkowska, Lucie Lafay-Cousin, Alexa Gozali, Nataliya Zhukova, Lisa Shane, Ignacio Gonzalez, Jonathan Finlay, David Malkin

Research output: Contribution to journalArticleResearchpeer-review

108 Citations (Scopus)

Abstract

Purpose: Choroid plexus carcinomas are pediatric tumors with poor survival rates and a strong, but poorly understood, association with Li-Fraumeni syndrome (LFS). Currently, with lack of biologic predictors, most children are treated with aggressive chemoradiation protocols. Patients and Methods: We established a multi-institutional tissue and clinical database, which enabled the analysis of specific alterations of the TP53 tumor suppressor and its modifiers in choroid plexus tumors (CPTs). We conducted high-resolution copy-number analysis to correlate these genetic parameters with family history and outcome. Results: We studied 64 patients with CPTs. All individuals with germline TP53 mutations fulfilled LFS criteria, whereas all patients not meeting these criteria harbored wild-type TP53 (P < .001). TP53 mutations were found in 50% of choroid plexus carcinomas (CPCs). Additionally, two sequence variants known to confer TP53 dysfunction, TP53 codon72 and MDM2 SNP309, coexisted in the majority of TP53 wild-type CPCs (92%) and not in TP53 mutated CPC (P = .04), which suggests a complementary mechanism of TP53 dysfunction in the absence of a TP53 mutation. High-resolution single nucleotide polymorphism (SNP) array analysis revealed extremely high total structural variation (TSV) in TP53-mutated CPC tumor genomes compared with TP53 wild-type tumors and choroid plexus papillomas (CPPs; P = .006 and .004, respectively). Moreover, high TSV was associated with significant risk of progression (P < .001). Five-year survival rates for patients with TP53-immunopositive and -immunonegative CPCs were 0% and 82 (± 9%), respectively (P < .001). Furthermore, 14 of 16 patients with TP53 wild-type CPCs are alive without having received radiation therapy. Conclusion: Patients with CPC who have low tumor TSV and absence of TP53 dysfunction have a favorable prognosis and can be successfully treated without radiation therapy.

Original languageEnglish
Pages (from-to)1995-2001
Number of pages7
JournalJournal of Clinical Oncology
Volume28
Issue number12
DOIs
Publication statusPublished - 20 Apr 2010
Externally publishedYes

Cite this